Clinical Trial

FMT+ QL1706+Bevacizumab+ XELOX as First-line Treatment for Advanced MSS-type Colon Cancer With Liver Metastasis

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The investigators plan to initiate a prospective, multicenter, phase II study, recruiting 30 patients with advanced colon cancer patients with liver metastasis who have not received prior treatment. This study plans to reconstruct intestinal microecology through fecal microbiota transplantation (FMT), and combine with QL1706+Bevacizumab+XELOX to enhance the anti-tumor immune effect at the same time, thereby improving the prognosis of colon cancer patients with liver metastasis.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2025-01-25; most recent amendment 2025-12-28.
Status change: Not Yet Recruiting → Recruiting 2025-12-28
Trial Details
NCT Number NCT06801665
Lead Sponsor Hua Jiang
Conditions Colon Cancer Liver Metastases
Enrollment 30 participants
Start Date 2025-04-17
Primary Completion 2027-02-01 (estimated)
Study Completion 2027-02-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-02